The OpenArray platform is ideally designed for pharmaceutical research, in that it is a cost effective screening platform, and as the numbers of samples increase, the OpenArray shows a very significant savings in time and money. Using expression-based markers for pre-clinical compound triage and ranking has become an accepted practice, with toxicogenomics being the most common application.
It has been shown that the OpenArray platform identifies differentially expressed genes below the sensitivity threshold of common chip and bead-based microarray platforms. The OpenArray Pathways gene panels allow you to use the OpenArray platform in a discovery mode; uncovering differentially expressed genes. Whether you are interested in toxicogenomics, drug MOA studies, or compound screening, the OpenArray platform will provide significant time and cost savings.
Resources
(Please click on image or link to download)
 |
Toxicogenomics screening of small molecules....Laura Vass, Janos Z. Kelemen, Liliana Z. Feher, Zsolt Lorincz, Sandor Kulin, Sandor Cseh, Gyorgy Dorman and Laszlo G. Puskas. Intl. J. Mol. Med. 23: 65-74. 2009. |
 |
ADME/Tox Product ProfileA summary of what the ADME/Tox panel contains and how it is used in toxicogenomic studies. |
 |
Nanoliter high-throughput RT-qPCR: a statistical ....James M. Dixon, Mariusz Lubomirski, Dhammika Amaratunga, Tom B. Morrison, Colin J. H. Brenan and Sergey E. Ilyin. BioTechniques 46:ii-viii. |
 |
OpenArray DLP Product ProfileA summary of how customers use the OpenArray platform with TaqMan® chemistry. In addition, there is information about our workflow and analysis software. |